These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35972722)

  • 1. Comparison of Good Clinical Practice Inspection Processes for Marketing Applications Between the United States Food and Drug Administration and the European Medicines Agency.
    Ayalew K; Ning YM; Foringer MJ; Leibenhaut S; Sellers JW; Yu B; Kronstein PD; Higgerson A; Mihaescu C; Rodriguez M; Williams L; Khin NA
    Ther Innov Regul Sci; 2023 Jan; 57(1):79-85. PubMed ID: 35972722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Descriptive Analysis of Good Clinical Practice Inspection Findings from U.S. Food and Drug Administration and European Medicines Agency.
    Sellers JW; Mihaescu CM; Ayalew K; Kronstein PD; Yu B; Ning YM; Rodriguez M; Williams L; Khin NA
    Ther Innov Regul Sci; 2022 Sep; 56(5):753-764. PubMed ID: 35610469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethics and the marketing authorization of pharmaceuticals: what happens to ethical issues discovered post-trial and pre-marketing authorization?
    Bernabe RDLC; van Thiel GJMW; Breekveldt NS; Gispen CC; van Delden JJM
    BMC Med Ethics; 2020 Oct; 21(1):103. PubMed ID: 33109181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GCP inspections in Germany and Europe following the implementation of the Directive 2001/20/EC.
    Göbel C; Baier D; Ruhfus B; Hundt F
    Ger Med Sci; 2009 Mar; 7():Doc01. PubMed ID: 19675741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
    Kühler TC; Bujar M; McAuslane N; Liberti L
    BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An FDA Analysis of Inspected Entities After Receiving Official Action Indicated Letters for Good Clinical Practice Violations.
    Jung M; Swann RM; Anantha MS; Jamali F
    Ther Innov Regul Sci; 2021 Sep; 55(5):907-917. PubMed ID: 34101151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
    Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
    Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Utility of Remote Inspections During the COVID-19 Health Emergency and in the Postpandemic Setting.
    Mofid S; Bolislis WR; Brading C; Hamilton N; Hardit C; Nagaoka M; Parain J; Zanta M; Kühler TC
    Clin Ther; 2021 Dec; 43(12):2046-2063. PubMed ID: 34740466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good clinical practice regulatory inspections: Lessons for Indian investigator sites.
    Marwah R; Van de Voorde K; Parchman J
    Perspect Clin Res; 2010 Oct; 1(4):151-5. PubMed ID: 21350732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
    Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
    Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why (not) go east? Comparison of findings from FDA Investigational New Drug study site inspections performed in Central and Eastern Europe with results from the USA, Western Europe, and other parts of the world.
    Caldron PH; Gavrilova SI; Kropf S
    Drug Des Devel Ther; 2012; 6():53-60. PubMed ID: 22563236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.
    Dörr P; Wadworth A; Wang T; McAuslane N; Liberti L
    Ther Innov Regul Sci; 2016 Nov; 50(6):734-742. PubMed ID: 30231740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory review of novel therapeutics--comparison of three regulatory agencies.
    Downing NS; Aminawung JA; Shah ND; Braunstein JB; Krumholz HM; Ross JS
    N Engl J Med; 2012 Jun; 366(24):2284-93. PubMed ID: 22591257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. US food and drug administration Indian site inspections: An experience.
    Mahajan P; D'Souza N; Bhatt A; Halbe V; Sharma R; Narayanswamy S; Bughediwala M
    Perspect Clin Res; 2012 Apr; 3(2):73-9. PubMed ID: 22701824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central site monitoring: results from a test of accuracy in identifying trials and sites failing Food and Drug Administration inspection.
    Lindblad AS; Manukyan Z; Purohit-Sheth T; Gensler G; Okwesili P; Meeker-O'Connell A; Ball L; Marler JR
    Clin Trials; 2014 Apr; 11(2):205-17. PubMed ID: 24296321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Data Integrity in Global Clinical Trials: Discussions From Joint US Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency Good Clinical Practice Workshop.
    Khin NA; Francis G; Mulinde J; Grandinetti C; Skeete R; Yu B; Ayalew K; Cho SJ; Fisher A; Kleppinger C; Ayala R; Bonapace C; Dasgupta A; Kronstein PD; Vinter S
    Clin Pharmacol Ther; 2020 Nov; 108(5):949-963. PubMed ID: 31958142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006-2015: a cohort study.
    Boucaud-Maitre D; Altman JJ
    Eur J Clin Pharmacol; 2016 Oct; 72(10):1275-1281. PubMed ID: 27473682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.